Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Int J Lepr Other Mycobact Dis ; 59(2): 242-7, 1991 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-2071981

RESUMEN

A male born in 1930 was diagnosed as smear-positive borderline leprosy in 1971, and was treated with dapsone and/or sulfamethoxypyridazine from 1972 to 1980 with clinical improvement. However, new skin lesions with smears strongly positive appeared in August 1980, and he was diagnosed as having downgraded to lepromatous (LL) leprosy, but the bacilli recovered from the skin biopsy were fully susceptible to both dapsone and rifampin by mouse foot pad technique. Between 1981 and 1983, the patient was treated with 24 months of rifampin 600 mg and dapsone 100 mg daily, supplemented with prothionamide 500 mg daily during the initial 3 months, and his skin lesions gradually improved during treatment with the combined regimen. Afterward, the patient was kept under surveillance without treatment. From 1984 to 1986, his skin smears were negative, and no bacilli could be found from a skin biopsy taken in 1985. Then in 1987, 52 months after stopping treatment, new skin lesions appeared with a high concentration of Mycobacterium leprae (2 x 10(6)/mg tissue). The drug-susceptibility test again demonstrated that the organisms were fully susceptible to both dapsone and rifampin. Apparently the relapse was due to remultiplication of drug-susceptible persisters.


Asunto(s)
Dapsona/uso terapéutico , Lepra Dimorfa/tratamiento farmacológico , Lepra Lepromatosa/tratamiento farmacológico , Protionamida/uso terapéutico , Rifampin/uso terapéutico , Adulto , Dapsona/farmacología , Quimioterapia Combinada , Humanos , Masculino , Mycobacterium leprae/efectos de los fármacos , Protionamida/farmacología , Recurrencia , Rifampin/farmacología , Sulfametoxipiridazina/uso terapéutico
2.
Acta Leprol ; 7(2): 163-8, 1990.
Artículo en Inglés | MEDLINE | ID: mdl-1699386

RESUMEN

In order to investigate a possible involvement of phagocytic cells in the various types of leprosy, we undertook the study of enzymatic activities in circulating leucocytes. The activity of leucocytic alkaline phosphatase was studied by histochemical techniques on blood smears in 31 patients presenting with leprosy and aged between 4 and 73, and in 11 non infected people. The 31 patients suffering from leprosy were distributed as following: 14 lepromatous leprosy of which 6 had not yet been treated and 8 were under treatment, 9 cases of tuberculoid leprosy of which 7 had been treated and 2 had not yet, 3 cases of borderline leprosy which had all been treated, and 5 patients whose form of leprosy was indeterminate (before treatment). The distribution of the different values we obtain shows a very significant difference (p less than 0.001) between patients with and without leprosy (respectively 33.8 +/- 7.3 and 109.8 +/- 12.5). Moreover, the decrease of the alkaline phosphatase activity correlated with the severity of the disease (47.2 +/- 11.4 in tuberculoid leprosy and 20.6 +/- 9.3 in lepromatous leprosy) thus suggesting that the evaluation of leucocytic alkaline phosphatase activity should be advised as a possible prognosis guide in indeterminate leprosy.


Asunto(s)
Fosfatasa Alcalina/metabolismo , Lepra Lepromatosa/patología , Lepra Tuberculoide/patología , Leucocitos/enzimología , Adolescente , Adulto , Anciano , Niño , Preescolar , Humanos , Lepra Dimorfa/patología , Persona de Mediana Edad , Neutrófilos/enzimología , Coloración y Etiquetado
3.
Int J Lepr Other Mycobact Dis ; 57(3): 607-14, 1989 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-2674301

RESUMEN

Among 39 strains of Mycobacterium leprae isolated from patients with multibacillary leprosy who relapsed after treatment with rifampin (RMP), 22 strains were resistant to RMP and 17 were susceptible. All of the RMP-resistant strains were recovered from patients who had been treated with more than 50 doses of RMP, usually given as monotherapy. RMP-susceptible strains were recovered from only six patients who had received more than 50 doses of RMP, and from 11 patients who had received no more than seven doses. The median time to relapse after the beginning of RMP therapy was 9 years (range 1-12 years) among the patients harboring RMP-resistant strains of M. leprae, and the median time to relapse after discontinuation of RMP treatment was 7 years (range 1-11 years) among the patients harboring RMP-susceptible strains. These data suggest that monotherapy with more than a few doses of RMP can be responsible for the emergence of RMP-resistant strains of M. leprae, thus emphasizing the need to employ RMP only in combination with other effective drugs in the chemotherapy of multibacillary leprosy.


Asunto(s)
Lepra/tratamiento farmacológico , Rifampin/uso terapéutico , Animales , Farmacorresistencia Microbiana , Femenino , Humanos , Masculino , Ratones , Mycobacterium leprae/efectos de los fármacos , Recurrencia , Rifampin/farmacología , Factores de Tiempo
5.
Int J Lepr Other Mycobact Dis ; 55(4): 672-9, 1987 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-3323369

RESUMEN

Primary and secondary dapsone resistance were studied among lepromatous patients living in Martinique, Guadeloupe, New Caledonia, Tahiti, Senegal, and Paris. Four hundred fifteen biopsies were taken from clinically active and bacteriologically positive (bacterial index greater than 2) patients in the 6-year period of 1980-1985. Among these, 280 biopsies that contained 5 x 10(4) acid-fast bacilli per ml with a morphological index of at least 0.10 were inoculated into the mouse foot pad, and 229 harbored infective Mycobacterium leprae. Among the 129 infective M. leprae isolated from new cases, 54% had some degree of dapsone resistance, a low degree being prominent in all cases. Among the 100 infective M. leprae isolated from relapsed cases, 79% had a high or an intermediate degree of dapsone resistance. The annual incidence of secondary dapsone resistance was estimated to be about 0.55% in Guadeloupe.


Asunto(s)
Dapsona/farmacología , Lepra/microbiología , Mycobacterium leprae/efectos de los fármacos , Dapsona/uso terapéutico , Farmacorresistencia Microbiana , Humanos , Lepra/tratamiento farmacológico , Martinica , Nueva Caledonia , Paris , Polinesia , Senegal , Indias Occidentales
8.
Nouv Rev Fr Hematol (1978) ; 28(2): 107-113, 1986.
Artículo en Francés | MEDLINE | ID: mdl-3016639

RESUMEN

Two HTLV-I associated adult T cell leukemia cases were observed in patient from Martinique (French West Indies). These case are similar to the clinical entity, described by Takatsuki in 1977 in Japan and by Catovsky in Caribbean patients, characterized by a lymphadenopathy, skin lesions and visceral involvement, hypercalcemia, an aggressive course, and poor prognosis. The malignant cells with T4 phenotype and often suppressive function, were pleomorphic, mature, with prominent nuclear irregularities. Systematic research of HTLV-I virus or antibodies in patients with this clinical picture, to measure the influence of this virus in T cell lymphoproliferative diseases in France and in French West Indies is required.


Asunto(s)
Anticuerpos Antivirales/aislamiento & purificación , Deltaretrovirus/inmunología , Leucemia/patología , Linfocitos T/ultraestructura , Adulto , Anciano , Médula Ósea/patología , Ensayo de Inmunoadsorción Enzimática , Humanos , Leucemia/inmunología , Ganglios Linfáticos/patología , Masculino , Piel/patología , Linfocitos T/inmunología
10.
Acta Leprol ; 1(4): 211-21, 1983.
Artículo en Francés | MEDLINE | ID: mdl-6377797

RESUMEN

This is the report of an experiment of leucocyte migration performed with BCG and Lepromin among three groups of people: - one group of leprotic people; - two groups of witnesses. The first one including people with BBS disease having not received corticoid treatment. The reaction against Lepromin are different, among the leprotic group of people from the non leprotic one. We have noticed in the leprotic group variations with time depending on the kind of treatment. This is a fact very interesting to point out. These findings should be showed right or wrong by other physicians.


Asunto(s)
Inhibición de Migración Celular , Lepra/inmunología , Leucocitos/inmunología , Humanos , Lepromina/inmunología , Lepra/tratamiento farmacológico , Mycobacterium bovis/inmunología , Rifampin/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA